AU2003286781B2 - Use of equol for treating androgen mediated diseases - Google Patents

Use of equol for treating androgen mediated diseases Download PDF

Info

Publication number
AU2003286781B2
AU2003286781B2 AU2003286781A AU2003286781A AU2003286781B2 AU 2003286781 B2 AU2003286781 B2 AU 2003286781B2 AU 2003286781 A AU2003286781 A AU 2003286781A AU 2003286781 A AU2003286781 A AU 2003286781A AU 2003286781 B2 AU2003286781 B2 AU 2003286781B2
Authority
AU
Australia
Prior art keywords
equol
phyto
dht
fed
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2003286781A
Other languages
English (en)
Other versions
AU2003286781A1 (en
Inventor
Robert J. Handa
Edwin Douglas Lephart
Trent D. Lund
Kenneth David Reginald Setchell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Children's Hospital Medical Center
Brigham Young University
Colorado State University Research Foundation
Original Assignee
Cincinnati Children's Hospital Medical Center
Brigham Young University
Colorado State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32230355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2003286781(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cincinnati Children's Hospital Medical Center, Brigham Young University, Colorado State University Research Foundation filed Critical Cincinnati Children's Hospital Medical Center
Publication of AU2003286781A1 publication Critical patent/AU2003286781A1/en
Priority to AU2005239984A priority Critical patent/AU2005239984B2/en
Assigned to COLORADO STATE UNIVERSITY RESEARCH FOUNDATION, BRIGHAM YOUNG UNIVERSITY, CHILDREN'S HOSPITAL MEDICAL CENTER reassignment COLORADO STATE UNIVERSITY RESEARCH FOUNDATION Amend patent request/document other than specification (104) Assignors: CHILDREN'S HOSPITAL MEDICAL CENTER, COLORADO STATE UNIVERSITY RESEARCH FOUNDATION RESEARCH FOUNDATION
Priority to AU2006347276A priority patent/AU2006347276B2/en
Application granted granted Critical
Publication of AU2003286781B2 publication Critical patent/AU2003286781B2/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Birds (AREA)
  • Physiology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
AU2003286781A 2002-10-29 2003-10-29 Use of equol for treating androgen mediated diseases Expired AU2003286781B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2005239984A AU2005239984B2 (en) 2002-10-29 2005-02-17 Use of equol for treating skin diseases
AU2006347276A AU2006347276B2 (en) 2002-10-29 2006-08-18 Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42246902P 2002-10-29 2002-10-29
US60/422,469 2002-10-29
PCT/US2003/034441 WO2004039327A2 (en) 2002-10-29 2003-10-29 Use of equol for treating androgen mediated diseases

Related Child Applications (2)

Application Number Title Priority Date Filing Date
AU2005239984A Division AU2005239984B2 (en) 2002-10-29 2005-02-17 Use of equol for treating skin diseases
AU2006347276A Division AU2006347276B2 (en) 2002-10-29 2006-08-18 Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders

Publications (2)

Publication Number Publication Date
AU2003286781A1 AU2003286781A1 (en) 2004-05-25
AU2003286781B2 true AU2003286781B2 (en) 2009-05-21

Family

ID=32230355

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003286781A Expired AU2003286781B2 (en) 2002-10-29 2003-10-29 Use of equol for treating androgen mediated diseases

Country Status (6)

Country Link
US (7) US20060122262A1 (enExample)
EP (1) EP1569636B1 (enExample)
JP (2) JP4889944B2 (enExample)
AU (1) AU2003286781B2 (enExample)
CA (1) CA2504682A1 (enExample)
WO (1) WO2004039327A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259220C1 (en) 2002-07-24 2017-08-24 Australian Health & Nutrition Association Limited Compositions and products containing enantiomeric equol, and methods for their making
US8668914B2 (en) * 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
EP1569636B1 (en) 2002-10-29 2017-12-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
SI2548455T1 (sl) * 2003-06-30 2016-11-30 Otsuka Pharmaceutical Co., Ltd. Sestavek, ki vsebuje mlečno kislinsko bakterijo, ki proizvaja ekvol
CA2564399A1 (en) * 2004-04-28 2005-11-17 Brigham Young University Use of equol for treating skin diseases
US20090104167A1 (en) * 2005-07-29 2009-04-23 Calpis Co., Ltd. Prophylactic/Ameliorating Agent for Menopausal Disorder and Functional Beverage/Food
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
NL1030571C2 (nl) * 2005-12-01 2006-04-27 Sara Lee De Nv Geurafgiftesysteem.
US8680140B2 (en) * 2006-08-02 2014-03-25 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of menopausal symptoms
JP2010501485A (ja) * 2006-08-18 2010-01-21 ブリガム・ヤング・ユニバーシティ 神経精神医学的または神経変性的な疾患または障害を予防または治療するためのエクオルの使用
JPWO2008126752A1 (ja) * 2007-04-09 2010-07-22 株式会社林原生物化学研究所 エクオール類を有効成分とする美白剤
TW201444815A (zh) * 2007-06-13 2014-12-01 大塚製藥股份有限公司 含雌馬酚（ｅｑｕｏｌ）之萃取物、其製造方法、雌馬酚萃取方法及含雌馬酚之食品（二）
EP2320889A4 (en) * 2008-08-15 2016-09-21 Nestec Sa METHOD FOR INCREASING THE CHANGE OF ENERGY REPLACEMENT
US20110091435A1 (en) * 2008-10-24 2011-04-21 University Of Southern California Phytoestrogenic formulations for alleviation or prevention of hair loss
JP6140682B2 (ja) * 2011-04-15 2017-05-31 ネステク ソシエテ アノニム サーチュイン遺伝子発現の調節方法
EP2699095A4 (en) * 2011-04-20 2015-04-15 Nestec Sa METHODS AND COMPOSITIONS THAT CAN BE USED TO PREVENT AND TREAT HYPERLEPTINEMIA
KR20160026042A (ko) * 2014-08-29 2016-03-09 (주)아모레퍼시픽 락토비온산을 함유하는 항스트레스용 또는 항상성 유지용 조성물
US9914718B2 (en) 2014-10-14 2018-03-13 Ausio Pharmaceuticals, Llc Anhydrous crystalline form of S-equol
JP6961694B2 (ja) 2016-07-26 2021-11-05 オージオ・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー Ｓ−エコールを用いてアルツハイマー病を診断するおよび治療する方法
US20190380998A1 (en) 2018-06-15 2019-12-19 The Board Of Regents Of The University Of Texas System Methods of treating and preventing melanoma with s-equol
AU2019285640A1 (en) 2018-06-15 2021-01-21 Board Of Regents Of The University Of Texas System Methods of treating and preventing breast cancer with S-equol
WO2020263989A1 (en) 2019-06-24 2020-12-30 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
WO2021217036A1 (en) * 2020-04-23 2021-10-28 Salem Aliasger K Gper proteolytic targeting chimeras
WO2021235278A1 (ja) * 2020-05-21 2021-11-25 株式会社ダイセル 閉経後で更年期障害を有しない満４０歳以上の女性のためのｑｏｌ改善用組成物
US12678421B2 (en) 2020-09-04 2026-07-14 Kyushu University, National University Corporation Composition for enhancing NAMPT gene expression
CN116531393A (zh) * 2023-04-03 2023-08-04 河北医科大学 一种预防高热惊厥发作的药物组合物
JP7596493B1 (ja) * 2023-11-24 2024-12-09 株式会社ダイセル 男性のｑｏｌの改善のための組成物
WO2025254155A1 (ja) * 2024-06-05 2025-12-11 株式会社Neron セロトニンの分泌促進用組成物、その飲食品、化粧品及び医薬品、並びにこれらの生産方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008503A1 (en) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
WO1998048790A1 (en) * 1997-04-28 1998-11-05 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
WO1999036050A1 (en) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4390559A (en) * 1979-04-11 1983-06-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
US5468501A (en) 1982-09-01 1995-11-21 Hercon Laboratories Corporation Article useful for administration of pharmacologically-active substances transdermally, orally or by means of implant
USRE34457E (en) * 1983-12-28 1993-11-30 Daicel Chemical Industries, Inc. Separating agent
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
JPH02124883A (ja) 1988-11-04 1990-05-14 Kitasato Inst:The 抗酸化作用を有するイソフラボン誘導体およびその製造法
CH679584A5 (enExample) * 1989-11-10 1992-03-13 Nestle Sa
TW279133B (enExample) 1990-12-13 1996-06-21 Elan Med Tech
JPH07506822A (ja) * 1992-05-19 1995-07-27 ノボゲン　リサーチ　ピーティーワイ　リミッテッド フィト−エストロゲン，類似体またはその代謝産物を含有する健康補助剤
CA2160371A1 (en) * 1993-04-16 1994-10-27 The Trustees Of Tufts College Method for treatment of menopausal and premenstrual symptoms
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5320949A (en) * 1993-10-12 1994-06-14 Protein Technologies International, Inc. Process for producing aglucone isoflavone enriched vegetable protein fiber
US5424331A (en) * 1994-06-10 1995-06-13 Bio-Virus Research Incorporated Pharmaceutical compositions and dietary soybean food products for the prevention of osteoporosis
WO1996010341A1 (en) 1994-10-03 1996-04-11 Schouten Industries B.V. Food and health products
US5523087A (en) * 1995-02-15 1996-06-04 Bio-Virus Research Incorporated Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
FR2731706B1 (fr) * 1995-03-14 1997-04-11 Cird Galderma Composes heterocycliques aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US5554519A (en) 1995-08-07 1996-09-10 Fermalogic, Inc. Process of preparing genistein
US5693018A (en) 1995-10-11 1997-12-02 Science Incorporated Subdermal delivery device
US5821361A (en) * 1996-06-11 1998-10-13 Protein Technologies International, Inc. Recovery of isoflavones from soy molasses
US5726034A (en) * 1996-09-06 1998-03-10 Protein Technologies International, Inc. Aglucone isoflavone enriched vegetable protein extract and protein material, and high genistein and daidzein content materials and process for producing the same
US6020471A (en) * 1996-09-13 2000-02-01 Abbott Laboratories Process for isolating phytoestrogens from plant protein
US5804234A (en) * 1996-09-13 1998-09-08 Suh; John D. Plant protein for nutritional products and method of making same
WO1998021946A1 (en) 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
US6146668A (en) * 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
CA2287965C (en) * 1997-05-01 2009-10-20 Graham Edmund Kelly Treatment or prevention of menopausal symptoms and osteoporosis
US6083526A (en) * 1997-05-22 2000-07-04 Gorbach; Sherwood L. Use of isoflavonoids in the treatment or prevention of postpartum depression
AU735713B2 (en) * 1997-08-08 2001-07-12 Otsuka Pharmaceutical Co., Ltd. Isoflavone-containing composition
US6521433B1 (en) * 1997-09-17 2003-02-18 E. I. Du Pont De Nemours And Company cDNA sequences from plants that encode activities associated with isoflavone biosynthesis
US5855892A (en) * 1997-09-19 1999-01-05 Potter; Susan M. Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
US5952374A (en) * 1997-09-29 1999-09-14 Protein Technologies International, Inc. Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function
US5942539A (en) * 1997-10-03 1999-08-24 Wake Forest University Methods of treating or preventing endometriosis with phytoestrogens
US5958946A (en) * 1998-01-20 1999-09-28 Styczynski; Peter Modulation of hair growth
US6004558A (en) * 1998-02-25 1999-12-21 Novogen, Inc. Methods for treating cancer with legume plant extracts
AUPP260798A0 (en) * 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
US6086915A (en) 1998-04-01 2000-07-11 Bioresponse L.L.C. Compositions and methods of adjusting steroid hormone metabolism through phytochemicals
WO1999061028A1 (en) 1998-05-27 1999-12-02 Gorbach Sherwood L Isoflavonoids for treatment and prevention of migraine headaches
CA2309179A1 (en) 1998-09-10 2000-03-16 Avon Products, Inc. Method and composition for reducing dermatological aging and for reduci ng bruising
CA2352510A1 (en) 1998-11-25 2000-06-02 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases
US6509043B1 (en) * 1998-11-25 2003-01-21 Nutri Pharma Asa Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of pulmonary diseases
EP1146798A2 (en) 1999-01-15 2001-10-24 Nutrahealth Ltd. (UK) Modified food products and beverages, and additives for food and beverages
AUPP868599A0 (en) 1999-02-15 1999-03-11 Novogen Research Pty Ltd Production of isoflavone derivatives
TR200102992T2 (tr) * 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
US6592910B1 (en) 1999-04-20 2003-07-15 Board Of Trustees, Southern Illinois University Methods of treating clinical diseases with isoflavones
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
EP1173443A1 (en) 1999-05-04 2002-01-23 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
US6401125B1 (en) 1999-08-05 2002-06-04 Nextpage, Inc. System and method for maintaining state information between a web proxy server and its clients
US6375994B1 (en) * 1999-08-20 2002-04-23 Sun Ten Laboratories, Inc. Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability
CA2416796A1 (en) * 2000-06-14 2001-12-20 Alla Shapiro Radioprotective agents
US6455568B2 (en) * 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AU2001271784A1 (en) 2000-07-06 2002-01-21 Wyeth Therapy for prosthesis-related bone degeneration
AU2001273125A1 (en) 2000-07-06 2002-01-21 American Home Products Corporation Combinations of bisphosphonates, estrogenic agents and optionally estrogens
EP1359940A2 (en) 2000-07-06 2003-11-12 Wyeth Combinations of statins, estrogenic agents and optionally estrogens
WO2002011675A2 (en) 2000-08-10 2002-02-14 Zelickson M D Brian D Organic nutrient for hair loss treatment
US6326366B1 (en) * 2000-08-22 2001-12-04 Protein Technologies International Hormone replacement therapy
US6565864B2 (en) * 2000-12-28 2003-05-20 Unilever Home & Personal Care Usa, A Division Of Conopco, Inc. Skin care product containing retinoids and phytoestrogens in a dual compartment package
US20020143059A1 (en) 2000-12-28 2002-10-03 Sreekumar Pillai Skin care product containing retinoids, retinoid booster and phytoestrogens in a dual compartment package
US20020192310A1 (en) 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
CN1526027A (zh) * 2001-02-02 2004-09-01 ̹�� 综合性金属加工设备
EP1234572B1 (de) * 2001-02-26 2013-10-30 Mibelle AG Cosmetics Isoflavon-Aglykone enhaltende Hautbehandlungsmittel
WO2002067988A2 (en) 2001-02-27 2002-09-06 The Regents Of The University Of Michigan Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor
DE10121375B4 (de) 2001-05-02 2014-01-16 Beiersdorf Ag Verwendung von Isoflavonoiden in kosmetischen oder dermatologischen Zubereitungen zur Prophylaxe vor und Behandlung von sensibler Haut
DE10122342A1 (de) 2001-05-09 2002-11-14 Beiersdorf Ag Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen
FR2825277B1 (fr) 2001-05-30 2004-10-15 Oreal Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
US6597597B2 (en) * 2001-11-13 2003-07-22 Hewlett-Packard Company Low temperature attaching process for MRAM components
AU2003259220C1 (en) * 2002-07-24 2017-08-24 Australian Health & Nutrition Association Limited Compositions and products containing enantiomeric equol, and methods for their making
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
CZ2005181A3 (cs) 2002-09-23 2005-08-17 Novogen Research Pty Ltd Léčba stárnutí pokožky vlivem světla a aktinického poškození pokožky
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
EP1569636B1 (en) 2002-10-29 2017-12-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
CA2564399A1 (en) 2004-04-28 2005-11-17 Brigham Young University Use of equol for treating skin diseases
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
WO2007066655A1 (ja) 2005-12-06 2007-06-14 Otsuka Pharmaceutical Co., Ltd. エクオール含有大豆胚軸発酵物、及びその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008503A1 (en) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Therapeutic methods and compositions involving isoflavones
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
WO1998048790A1 (en) * 1997-04-28 1998-11-05 Anticancer, Inc. Use of genistein and related compounds to treat certain sex hormone related conditions
US6060070A (en) * 1997-06-11 2000-05-09 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of aging skin and wrinkles
WO1999036050A1 (en) * 1997-12-24 1999-07-22 Novogen Research Pty. Ltd. Compositions and method for protecting skin from uv induced immunosuppression and skin damage

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kinjo, J. 'Phytoestrogens'. Japanese Journal of Clinical Medicine, 2000, Vol. 58, No. 12 pgs. 2434-2438. *
Widyarini, S. et al. 'Isoflavonoid compounds from red clover (trifolium pratense) protect from inflammation and immune supression induced by UV radiation' Photochemistry and Photobiology, Vol. 74, No. 3, Sept 2001 (2001-09), pgs. 465-470. *

Also Published As

Publication number Publication date
US20060122262A1 (en) 2006-06-08
US20160256436A1 (en) 2016-09-08
JP2012021005A (ja) 2012-02-02
US8450364B2 (en) 2013-05-28
US20180185326A1 (en) 2018-07-05
US9408825B2 (en) 2016-08-09
JP4889944B2 (ja) 2012-03-07
US10111855B2 (en) 2018-10-30
US9089547B2 (en) 2015-07-28
US20120264821A1 (en) 2012-10-18
WO2004039327A3 (en) 2004-10-07
JP2006508942A (ja) 2006-03-16
JP5535999B2 (ja) 2014-07-02
WO2004039327A2 (en) 2004-05-13
US9889116B2 (en) 2018-02-13
US8153684B2 (en) 2012-04-10
AU2003286781A1 (en) 2004-05-25
EP1569636A2 (en) 2005-09-07
US20150342924A1 (en) 2015-12-03
US20100087519A1 (en) 2010-04-08
CA2504682A1 (en) 2004-05-13
EP1569636B1 (en) 2017-12-13
US20140135387A1 (en) 2014-05-15
EP1569636A4 (en) 2007-07-04
WO2004039327A8 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
US10111855B2 (en) Use of equol for treating androgen mediated diseases
Kenneth Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones
US9408824B2 (en) Compositions and products containing S-equol, and methods for their making
AU767691B2 (en) Hydroxymatairesinol in cancer prevention
US8668914B2 (en) Use of equol for treating skin diseases
JP2013006874A (ja) 皮膚疾患を処置するためのエクオールの使用
US8580846B2 (en) Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
WO2001001969A2 (en) Methods of treating and/or suppressing weight gain
AU2006347276B2 (en) Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-APPLICANTS FROM COLORADO STATE UNIVERSITY RESEARCH FOUNDATION RESEARCH FOUNDATION TO COLORADO STATE UNIVERSITY RESEARCH FOUNDATION AND FROM TECHNOLOGY TRANSFER OFFICE TO BRIGHAM YOUNG UNIVERSITY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired